Sign In
Buy LGND
$234.40
+1.64 (+0.705%)
At Close: Jun 03, 2026
B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND
03:48am, Monday, 27'th Apr 2026
B. Metzler seel. Sohn and Co. AG purchased a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) during the undefined quarter, according to the company in its most recent fili
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
07:00am, Wednesday, 22'nd Apr 2026
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026.
PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it wil
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
07:00am, Tuesday, 14'th Apr 2026
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla.,
Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)
01:44am, Monday, 13'th Apr 2026
Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND
03:40am, Monday, 06'th Apr 2026
Aberdeen Group plc cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 37.1% during the fourth quarter, according to the company in its most recent disclosure with the
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of “Moderate Buy” by Brokerages
02:38am, Monday, 06'th Apr 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. One a
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $94,441.41 in Stock
05:57am, Sunday, 05'th Apr 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) Director John Kozarich sold 467 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares
04:48am, Friday, 03'rd Apr 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average
CLO Sells LGND 5,000 Shares for $1.0 Million
07:41pm, Monday, 30'th Mar 2026
5,000 shares were sold on March 4, 2026, through an option exercise and immediate disposition, yielding a transaction value of ~$1.03 million at around $206.35 per share. The sale represented 11.94% o
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know
07:20pm, Friday, 27'th Mar 2026
A Ligand insider sold 3,057 shares of common stock on March 11, 2026, for $688,000. The transaction represented 12.70% of his direct common stock holdings, reducing his position from 24,067 to 21,010
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
07:00am, Thursday, 26'th Mar 2026
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown
Arecor receives $500k milestone payment from Ligand as royalty deal delivers
03:28am, Thursday, 26'th Mar 2026
Arecor Therapeutics PLC (AIM:AREC), the Cambridge-based biotech focused on diabetes and cardiometabolic treatments, has received a $500,000 commercial milestone payment from Ligand Pharmaceuticals und
Congress Asset Management Co. Sells 187,248 Shares of Ligand Pharmaceuticals Incorporated $LGND
01:39pm, Tuesday, 24'th Mar 2026
Congress Asset Management Co. lowered its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 28.1% during the undefined quarter, according to the company in its most recent discl
Acuitas Investments LLC Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND
03:24am, Wednesday, 18'th Mar 2026
Acuitas Investments LLC lowered its position in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 32.2% during the third quarter, according to the company in its most recent disclosure with the Se
